The NEOSTAR trial analyzed immune profiling of resected tumor tissues and found that CD3+ TILs, CD3+CD8+ TILs, and CD3+CD8+CD45RO+ memory TILs were significantly higher in tumors treated with nivolumab + ipilimumab than in those treated with monotherapy. This evidence concerns the gene CD8A and neoplasm.